<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00362388</url>
  </required_header>
  <id_info>
    <org_study_id>EMRTCC-ISQ</org_study_id>
    <nct_id>NCT00362388</nct_id>
  </id_info>
  <brief_title>Cell Therapy in Chronic Ischemic Heart Disease</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Intramyocardial Injection of Autologous Bone-Marrow Cells in Patients With Severe, Chronic Ischemic Heart Disease Undergoing Coronary Bypass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ministry of Health, Brazil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to test the hypothesis that direct injection of bone-marrow cells in&#xD;
      the heart may increase the number of blood vessels, ameliorating the heart's performance, and&#xD;
      relieving patients from symptoms like angina and/or shortness of breath.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe ischemic heart disease (IHD) remains a clinical challenge; many patients with IHD have&#xD;
      undergone myocardial revascularization procedures (either percutaneous or surgical) but still&#xD;
      remain symptomatic despite maximally tolerated medical therapy. Others are considered&#xD;
      non-optimal candidates for a complete myocardial revascularization procedure due to the&#xD;
      extension and diffuseness of the disease.&#xD;
&#xD;
      Cell therapy with autologous bone marrow-derived cells (BMC) is a novel therapeutic strategy&#xD;
      being tested for many cardiovascular diseases, including heart failure, acute myocardial&#xD;
      infarction, chronic ischemic heart disease.&#xD;
&#xD;
      The primary objective of this study is to assess the efficacy of intramyocardial injection of&#xD;
      autologous BMC on the myocardial perfusion and left ventricular function as an adjunctive&#xD;
      therapy (compared to placebo) in patients undergoing coronary artery bypass surgery (CABG).&#xD;
&#xD;
      The secondary objective of this study is to assess the effect of intramyocardial injection of&#xD;
      autologous BMC on functional class (angina/heart failure), functional capacity, global and&#xD;
      cardiovascular mortality, and quality of life in patients undergoing coronary artery bypass&#xD;
      surgery (CABG).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low enrollling&#xD;
  </why_stopped>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Anticipated">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in the ischemic score (global/regional) at 12 months; increase in left ventricle ejection fraction (LVEF) at 12 months.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause and cardiovascular mortality during the first year; increase in VO2max, increase in quality of life, reduction in angina/heart failure functional class at 12 months; percentage of patients with a 5% increase in LVEF at 6 and 12 months.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intramyocardial injection of autologous bone marrow cells</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of chronic, severe, diffuse, multivessel atherosclerotic coronary artery&#xD;
             disease (CAD) referred for CABG.&#xD;
&#xD;
          -  Echocardiogram-assessed LVEF between 25 and 55% (Simpson's rule).&#xD;
&#xD;
          -  Angina (or equivalent) functional class II to IV (Canadian Cardiovascular Society)&#xD;
             despite maximally tolerated medical therapy.&#xD;
&#xD;
          -  Abnormal myocardial perfusion tests:&#xD;
&#xD;
             i. Cardiac scintigraphy ii. Magnetic resonance imaging iii. Dobutamine-atropine&#xD;
             stress-echocardiogram&#xD;
&#xD;
          -  Non-candidates for a percutaneous coronary intervention (PCI) due to ANY of the&#xD;
             following:&#xD;
&#xD;
             i. High risk lesion ii. Extensive lesion iii. Diffuse, small vessel disease&#xD;
&#xD;
          -  Non-candidates for a complete CABG, or candidates for a complete CABG in whom,&#xD;
             according to an expert panel, there is a high probability of failure of the grafts due&#xD;
             to the extension and severity of the disease, with diffuse, small vessel involvement.&#xD;
&#xD;
          -  To provide a signed, written informed consent, according to the National Guidelines&#xD;
             for Clinical Trials.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe valve heart disease requiring surgical repair.&#xD;
&#xD;
          -  Serologic diagnostic of Chagas' disease.&#xD;
&#xD;
          -  Symptoms of heart failure, even from an ischemic etiology, in the absence of&#xD;
             objectively documented myocardial ischemia.&#xD;
&#xD;
          -  Malignant ventricular arrhythmias (like VT), unless an ICD have been placed.&#xD;
&#xD;
          -  Any acute coronary syndrome in the past 3 months.&#xD;
&#xD;
          -  End-stage renal disease requiring maintenance dialysis.&#xD;
&#xD;
          -  History of neoplasia.&#xD;
&#xD;
          -  Drug or alcohol abuse.&#xD;
&#xD;
          -  Life expectancy below 2 years.&#xD;
&#xD;
          -  Enrollment in any cell therapy trial in the past 2 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio A. de Oliveira, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Institute (InCor), Hospital das Clinicas, University of São Paulo Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Eduardo Krieger, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Heart Institute (InCor), Hospital das Clinicas, University of São Paulo Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto do Coração de Pernambuco do Real Hospital Português de Beneficência</name>
      <address>
        <city>Recife</city>
        <state>PE</state>
        <zip>52010-040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80010-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Cardiologyca C. Constantini</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80320-320</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cardiologia Laranjeiras (INCL)</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>22240-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pró-Cardíaco</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>22280-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Institute (InCor), Hospital das Clínicas, University of São Paulo Medical School</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.incor.usp.br</url>
    <description>Link to the Heart Institute (InCor), in São Paulo, Brazil (in Portuguese).</description>
  </link>
  <link>
    <url>http://www.incl.rj.saude.gov.br</url>
    <description>Link to the Instituto Nacional de Cardiologia Laranjeiras (INCL), in Rio de Janeiro, Brazil (In Portuguese).</description>
  </link>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>August 8, 2006</study_first_submitted>
  <study_first_submitted_qc>August 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2006</study_first_posted>
  <last_update_submitted>January 26, 2010</last_update_submitted>
  <last_update_submitted_qc>January 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2010</last_update_posted>
  <keyword>Coronary artery disease</keyword>
  <keyword>Ischemic heart disease</keyword>
  <keyword>Angiogenesis</keyword>
  <keyword>Cells</keyword>
  <keyword>Cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

